New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
07:22 EDTINCYIncyte reports Q1 EPS (21c), consensus (18c)
Reports Q1 total revenues $89.8M, consensus $97.19M. The company said, "The increase in net loss in Q1 as compared to the same period of 2013 is primarily due to the company’s broad investment in its clinical pipeline and additional costs related to the commercialization of Jakafi in MF and preparation for the anticipated launch in PV."
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
07:34 EDTINCYIncyte, Merck expand clinical partnership towards Phase 3 Keytruda study
Subscribe for More Information
October 2, 2015
07:31 EDTINCYIncyte to present new data on immuno-oncology portfolio at SITC
Subscribe for More Information
October 1, 2015
07:31 EDTINCYLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
08:30 EDTINCYIncyte to join Nasdaq-100 Index beginning Oct. 7, to replace Altera
Nasdaq yesterday announced that Incyte Corporation (INCY), will become a component of the NASDAQ-100 Index and the NASDAQ-100 Equal Weighted Index prior to market open on Wednesday, October 7, 2015. Incyte Corporation will replace Altera Corporation (ALTR). Incyte Corporation is headquartered in Palo Alto, California, and has a market capitalization of approximately $19B.
September 29, 2015
06:47 EDTINCYEli Lilly and Incyte's baricitinib Phase 3 study met primary objective
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use